Antibody (T cell) showed no clear difference in recurrent rejection compared with steroid (stratified by antibody type) (moderate certainty).
Antibody showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by antibody type) (low certainty).
Antibody showed no clear difference in recurrent rejection compared with other antibody (stratified by antibody type) (low certainty).
Antibody showed no clear difference in graft loss censored for death compared with other antibody (stratified by antibody type) (low certainty).
Antibody showed no clear difference in graft loss or death with a functioning graft compared with other antibody (stratified by antibody type) (low certainty).
Antibody showed no clear difference in death compared with other antibody (stratified by antibody type) (low certainty).
It is very uncertain whether antibody changes treatment adverse events: bacterial infection compared with other antibody (stratified by antibody type) (very low certainty).
Antibody (T cell) showed no clear difference in graft loss or death with a functioning graft compared with steroid (stratified by antibody type) (low certainty).
Antibody (T cell) showed no clear difference in graft loss censored for death compared with steroid (stratified by antibody type) (low certainty).
It is very uncertain whether antibody (T cell) changes death compared with steroid (stratified by antibody type) (very low certainty).
It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).
Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).
Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).
It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).
The intervention showed no clear difference in death (including CNI) (low certainty).
The intervention may leads to higher biopsy‐proven CAN (ESW with alemtuzumab only) (low certainty).
The intervention showed no clear difference in CMV infection (all studies) (low certainty).
The intervention showed no clear difference in NODAT (ESW alemtuzumab only) (low certainty).
It is very uncertain whether the intervention changes malignancy (all studies) (very low certainty).